Central Drugs Standard Control Organization refuses to give RTI reply in Chandigarh

Drug manufacturers and the chemist who supplied Propofol drugs in PGI after which five patients died have not been found guilty Central Drugs Standard Control Organization (CDSCO) Baddi in its RTI reply, refused to share details. Instead, it said the matter is under investigation.

The case, which was first highlighted by TOI in September last year, has still not named any official or drug suppliers. Even though the drug tested as sub-standard in quality and was also found to be toxic by the Regional Drug Laboratory. CDSCO laboratory in Chandigarh, its manufacturers have not been labelled as guilty. The chemist who dispensed the drug was given a clean chit two months after the incident by the drug controller and licensing authority, Chandigarh.

There was no link established between the deaths and the drug. As the chemist is not the manufacturer or marketing agent, he cannot be held culpable under any licensing authority said Dr Suman Singh, drug controller and licensing authority UT.

The PGI did not lodge a police complaint or conduct an autopsy as the patients’ relatives had denied the same. In the absence of an autopsy report, the deaths cannot be linked with the drug. The internal report of the PGI found the drug as a probable cause. The PGI cannot lodge any complaint with the police as there was no legally strong evidence said a faculty.

Sector 22 resident Prince Bhadula filed an RTI application in the case, in reply to which CDSCO Baddi said, The matter is under investigation and hence cannot be disclosed at this stage. Prince said, I had asked about the status of the case lying with the CDSCO through the RTI. The manufacturers, Nixi laboratories private limited, denied that Propofol from their laboratory caused adverse drug reaction or contamination.

They blamed it on mishandling of the drug by healthcare workers and their competitors maligning their image. Till date, not even relatives of the patients who died or had complications have been compensated by PGI or drug manufacturers as no one has taken responsibility said an official in the PGI administration.

Related Posts

  • Pharma
  • July 26, 2024
  • 128 views
US FDA Finds Data Integrity, Sterility Problems At Brassica Pharma

Maryland: The US Food and Drug Administration (FDA) has warned Brassica Pharma for numerous good manufacturing practice (GMP) violations, including multiple instances of employees falsifying sterility and environmental monitoring data and…

  • Pharma
  • July 26, 2024
  • 125 views
Indian National Charged With Selling Counterfeit Cancer Drugs

HOUSTON: A federal grand jury has returned an indictment charging an Indian national with selling and shipping tens of thousands of dollars in counterfeit oncology pharmaceuticals into the United States,…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

US FDA Finds Data Integrity, Sterility Problems At Brassica Pharma

US FDA Finds Data Integrity, Sterility Problems At Brassica Pharma

Indian National Charged With Selling Counterfeit Cancer Drugs

Indian National Charged With Selling Counterfeit Cancer Drugs

ICMR Releases 32 New Treatment Standards For Treating Common And Serious Diseases

ICMR Releases 32 New Treatment Standards For Treating Common And Serious Diseases

BIS Sanctioned 82 Medical Device Projects To Develop Standards

BIS Sanctioned 82 Medical Device Projects To Develop Standards

Anti-Narcotics Task Force Will Be Formed Soon In Rajasthan: HM

Anti-Narcotics Task Force Will Be Formed Soon In Rajasthan: HM

‘Sunrise’ MedTech Industry in India & ‘Clouds’ strangling it, Brainstormed in PHD

‘Sunrise’ MedTech Industry in India & ‘Clouds’ strangling it, Brainstormed in PHD